.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP09_Dasabuvir.Dasabuvir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP09_Dasabuvir.Dasabuvir| name: | Dasabuvir |
| ATC code: | J05AP09 | route: | oral |
| n-compartments | 2 |
Dasabuvir is a non-nucleoside NS5B polymerase inhibitor used in combination with other antiviral agents for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotypes 1a and 1b. It was approved as part of fixed-dose combination therapies (such as Viekira Pak) but is no longer widely marketed following advances in HCV therapies.
Pharmacokinetic parameters in healthy adult subjects after single oral administration of dasabuvir.
Mensing, S, et al., & Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS journal 18(1) 270–280. DOI:10.1208/s12248-015-9846-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26597291
Gentile, I, et al., & Borgia, G (2014). Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. Reviews on recent clinical trials 9(2) 115–123. DOI:10.2174/1574887109666140529222602 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24882169
Lam, JT, & Salazar, L (2016). New combination antiviral for the treatment of hepatitis C. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 73(14) 1042–1050. DOI:10.2146/ajhp150163 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27217519